Impact of prior treatment on PFS for relapsed/refractory mantle cell lymphoma patients randomized to lenalidomide vs investigator's choice: a subgroup analysis of the phase II Mcl-002 (Sprint) study.
Authors
Trneny, MLamy, T
Walewski, J
Belada, D
Mayer, J
Radford, John A
Jurczak, W
Morschhauser, F
Alexeeva, J
Rule, S
Biyukov, T
Patturajan, M
Bravo, MLC
Arcaini, L
Affiliation
Department of Hematology, Charles University Hospital, PragueIssue Date
2015